Company Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Equities
600196
CNE000000X38
Pharmaceuticals
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.71 CNY | +2.24% | +4.27% | -5.27% |
04-24 | Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator | MT |
04-18 | China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy | MT |
Business Summary
- research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases;
- sale of medical equipments and diagnosis products (17.3%);
- medical and hospital services (10.5%);
- other (0.1%).
China accounts for 72.9% of net sales.
Number of employees: 40,370
Sales per Business
CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
73.0
%
| 30,812 | 70.1 % | 30,222 | 73.0 % | -1.91% |
Medical and Health Services
16.1
%
| 6,080 | 13.8 % | 6,672 | 16.1 % | +9.74% |
Medical Devices and Medical Diagnosis
10.6
%
| 6,949 | 15.8 % | 4,390 | 10.6 % | -36.83% |
Other
0.3
%
| 110 | 0.3 % | 115 | 0.3 % | +4.48% |
Sales per region
CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
China
74.9
%
| 30,013 | 68.3 % | 31,029 | 74.9 % | +3.38% |
Other Countries or Regions
25.1
%
| 13,938 | 31.7 % | 10,371 | 25.1 % | -25.60% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
De Yong Wen
CEO | Chief Executive Officer | 52 | - |
Dong Ming Li
PSD | President | 55 | 28/10/20 |
Yi Fang Wu
CHM | Chairman | 54 | 31/03/04 |
Ke Xin Wang
CHM | Chairman | 60 | 28/10/20 |
Shirley Wu
DFI | Director of Finance/CFO | 44 | 31/12/16 |
Hequn Yin
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Qi Yu Chen
BRD | Director/Board Member | 52 | 31/03/94 |
Fang Yao
BRD | Director/Board Member | 54 | 08/04/10 |
Rong Li Feng
PRN | Corporate Officer/Principal | 49 | - |
Ai Min Hui
SAM | Sales & Marketing | 61 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Fang Yao
BRD | Director/Board Member | 54 | 08/04/10 |
Qi Yu Chen
BRD | Director/Board Member | 52 | 31/03/94 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | - |
Yi Fang Wu
CHM | Chairman | 54 | 31/03/04 |
Xiao Liang Xu
BRD | Director/Board Member | 51 | 24/06/19 |
Ke Xin Wang
CHM | Chairman | 60 | 28/10/20 |
Dong Hui Pan
BRD | Director/Board Member | 54 | 29/06/20 |
De Yong Wen
CEO | Chief Executive Officer | 52 | - |
Qian Ren
CHM | Chairman | 55 | 10/01/18 |
Quan Di Wang
BRD | Director/Board Member | 74 | 10/06/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 551,940,500 | 473,969,000 ( 85.87 %) | 0 | 63.42 % |
Stock B | 1 | 2,122,427,597 | 1,222,025,582 ( 57.58 %) | 1,969,386 ( 0.0928 %) |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
GLAND PHARMA LIMITED 57.86% | 95,293,894 | 57.86% | 2,104,515,143 $ |
SISRAM MEDICAL LTD 71.42% | 334,504,800 | 71.42% | 150,871,700 $ |
35,523,439 | 21.74% | 61,819,665 $ | |
YSB INC. 7.61% | 48,721,760 | 7.61% | 50,549,313 $ |
17,186,726 | 0.99% | 12,389,223 $ |
Company contact information
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Building A No. 1289 Yishan Road
200233, Shanghai
+86 21 3398 7000
http://www.fosunpharma.comGroup companies
Name | Category and Sector |
---|---|
Chindex Hong Kong Ltd.
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.27% | 7.65B | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- 600196 Stock
- Company Shanghai Fosun Pharmaceutical (Group) Co., Ltd.